Statistical table
| Figure | Description | Data structure | Type of test | Power (statistic) |
|---|---|---|---|---|
| Fig. 3A | β3-tubulin (CreOFF DNA) | Normal distribution | Two-way ANOVA | F(3,24) = 5.3 |
| Fig. 3A | β-actin (CreOFF DNA) | Normal distribution | Two-way ANOVA | F(3,24) = 4.6 |
| Fig. 3A | Double (CreOFF DNA) | Normal distribution | Two-way ANOVA | F(3,24) = 7.6 |
| Fig. 3A | Incorrect (CreOFF DNA) | Normal distribution | Two-way ANOVA | F(3,24) = 4.2 |
| Fig. 3B | β3-tubulin (DNA) | Normal distribution | ANOVA | F(7,16) = 3.9 |
| Fig. 3B | β-actin (DNA) | Normal distribution | ANOVA | F(7,16) = 3.4 |
| Fig. 3B | Double (DNA) | Normal distribution | ANOVA | F(7,16) = 2.3 |
| Fig. 3B | Incorrect (DNA) | Normal distribution | ANOVA | F(7,16) = 0 |
| Fig. 3E | Donor copy number | Normal distribution | Linear regression | F(1,10) = 7.2 |
| Fig. 4B | β3-tubulin (4OH-tamoxifen) | Normal distribution | Two-way ANOVA | F(3,24) = 0.49 |
| Fig. 4B | β-actin (4OH-tamoxifen) | Normal distribution | Two-way ANOVA | F(3,24) = 27.6 |
| Fig. 4B | Double (4OH-tamoxifen) | Normal distribution | Two-way ANOVA | F(3,24) = 14.4 |
| Fig. 4B | Incorrect (4OH-tamoxifen) | Normal distribution | Two-way ANOVA | F(3,24) = 3.1 |
| Fig. 4C | Double (lenti vs tamoxifen) | Normal distribution | Unpaired t test | t(13) = 1.8 |
| Fig. 5D | GluA1 (DNA) | Normal distribution | Kruskal–Wallis | Statistic = 9.2 |
| Fig. 5D | Cav2.3 (DNA) | Normal distribution | Kruskal–Wallis | Statistic = 1.6 |
| Fig. 5D | Double (DNA) | Normal distribution | Kruskal–Wallis | Statistic = 5.7 |
| Fig. 5D | Incorrect (DNA) | Normal distribution | Kruskal–Wallis | Statistic = 3.0 |
| Fig. 5E | Time (DIV) | Normal distribution | Two-way ANOVA | F(3,35) = 12.5 |
| Fig. 5E | Knock-in | Normal distribution | Two-way ANOVA | F(2,35) = 13.3 |
| Fig. 5E | Interaction | Normal distribution | Two-way ANOVA | F(6,35) = 3.2 |
| Fig. 5G | GluA1 | Normal distribution | ANOVA | F(2,6) = 0.099 |
| Fig. 5G | Cav2.3 | Normal distribution | ANOVA | F(2,6) = 2.4 |
| Fig. 5G | Double | Normal distribution | ANOVA | F(2,6) = 0.56 |
| Fig. 5G | Incorrect | Normal distribution | ANOVA | F(2,6) = 5.7 |
| Fig. 6C | Nanodomain-PSD distance | Nonuniform | Mann–Whitney | Statistic = 426143 |
| Fig. 6D | PSD size vs nanodomain distance | Nonuniform | Linear regression | F(1,642) = 13.8 |
| Fig. 6F | PSD size vs co-localization | Nonuniform | Linear regression | F(1,654) = 155.7 |
| Fig. 6G | PSD95 (nanodomain enrichment) | Normal distribution | One-sample t test | t(11) = 8.1 |
| Fig. 6G | GluA1 (nanodomain enrichment) | Normal distribution | One-sample t test | t(11) = 11.6 |
| Fig. 7F | Mobile GluA1 before/after | Normal distribution | Paired t test | t(5) = 3.4 |
| Fig. 7G | GluA1 synaptic enrichment | Normal distribution | Paired t test | t(5) = 1.4 |
| Extended Data Fig. 1-1D | β3-tubulin (2A vs lenti) | Normal distribution | Unpaired t test | t(13) = 0.69 |
| Extended Data Fig. 1-1D | β-actin (2A vs lenti) | Normal distribution | Unpaired t test | t(13) = 1.1 |
| Extended Data Fig. 1-1D | Double (2A vs lenti) | Normal distribution | Unpaired t test | t(13) = 0.64 |
| Extended Data Fig. 1-1D | Incorrect (2A vs lenti) | Normal distribution | Unpaired t test | t(13) = 2.7 |
| Extended Data Fig. 1-1E | β3-tubulin (2A vs lenti) | Normal distribution | Unpaired t test | t(44) = 4.5 |
| Extended Data Fig. 1-1E | β-actin (2A vs lenti) | Normal distribution | Unpaired t test | t(30) = 0.29 |
| Extended Data Fig. 3-1A | GluA1 (CreOFF DNA) | Normal distribution | Two-way ANOVA | F(3,24) = 2.2 |
| Extended Data Fig. 3-1A | PSD95 (CreOFF DNA) | Normal distribution | Two-way ANOVA | F(3,24) = 2.5 |
| Extended Data Fig. 3-1A | Double (CreOFF DNA) | Normal distribution | Two-way ANOVA | F(3,24) = 1.3 |
| Extended Data Fig. 3-1A | Incorrect (CreOFF DNA) | Normal distribution | Two-way ANOVA | F(3,24) = 0.33 |
| Extended Data Fig. 3-1C | β3-tubulin (plasmid) | Normal distribution | Two-way ANOVA | F(2,24) = 18.6 |
| Extended Data Fig. 3-1C | β-actin (plasmid) | Normal distribution | Two-way ANOVA | F(2,24) = 0.72 |
| Extended Data Fig. 3-1C | Double (plasmid) | Normal distribution | Two-way ANOVA | F(2,24) = 11.4 |
| Extended Data Fig. 3-1C | Incorrect (plasmid) | Normal distribution | Two-way ANOVA | F(2,24) = 0 |
| Extended Data Fig. 4-1B | PSD95 (4OH-tamoxifen) | Normal distribution | Two-way ANOVA | F(3,24) = 0.16 |
| Extended Data Fig. 4-1B | GluA1 (4OH-tamoxifen) | Normal distribution | Two-way ANOVA | F(3,24) = 4.8 |
| Extended Data Fig. 4-1B | Double (4OH-tamoxifen) | Normal distribution | Two-way ANOVA | F(3,24) = 1.7 |
| Extended Data Fig. 4-1B | Incorrect (4OH-tamoxifen) | Normal distribution | Two-way ANOVA | F(3,24) = 1 |
| Extended Data Fig. 6-1A | Number of nanodomains | Normal distribution | Unpaired t test | t(22) = 10.0 |
| Extended Data Fig. 6-1A | Nanodomain diameter | Normal distribution | Unpaired t test | t(22) = 7.9 |
| Extended Data Fig. 7-1D | Mobile GluA1 (no rapalog) | Normal distribution | Paired t test | t(5) = 0.18 |
Overview of all statistical tests that were performed, including figure number, description, data structure, the type of test and the power (statistic).